Other clinical studies are ongoing with various AAV serotypes (AAV1, AAV8, AAV9) and transgenes (encoding mini-dystrophin, micro-dystrophin, follistatin, and β-1,4-N-acetylgalactosaminyltransferase 2) to treat Duchenne muscular dystrophy and with the MTM1 transgene to treat patients with X-linked myotubular myopathy [132,133]. This evidence concerns the gene DMD and Duchenne muscular dystrophy.